Diagnosis and Management of Monoclonal Gammopathies

Introduction to Monoclonal Gammopathies

Immunofixation electrophoresis (IFE) is more sensitive than serum protein electrophoresis (SPE) for detecting small amounts of monoclonal proteins, as stated by the International Myeloma Society 1
The kappa:lambda ratio, determined by serum free light chain (SFLC) assay, is an independent prognostic factor when outside the normal range (< 0.26 or > 1.65), according to the European Society for Medical Oncology 2
Abnormal SFLC ratio is associated with a higher risk of progression to multiple myeloma, as stated by the American Society of Hematology 3

Quantitative immunoglobulins (IgG, IgA, IgM) help evaluate potential monoclonal gammopathy and identify immunoparesis, a risk factor for progression, according to the National Comprehensive Cancer Network 3
The Mayo Clinic model is used for risk stratification of Monoclonal Gammopathy of Undetermined Significance (MGUS) based on M-protein concentration, immunoglobulin type, and SFLC ratio, as recommended by the Mayo Clinic 3
Initial testing should include serum protein electrophoresis (SPEP) with immunofixation electrophoresis (IFE) to identify and characterize monoclonal protein bands, as recommended by the National Comprehensive Cancer Network 4, 5
Additional tests, such as serum free light chain (FLC) assay, quantitative immunoglobulins, and 24-hour urine collection for total protein, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE), may be considered based on SPEP results 4, 5

Low-risk MGUS patients should be followed up at 6 months, and if stable, every 1-2 years, according to the International Myeloma Society 3
Non-low-risk MGUS patients should be followed up at 6 months, and annually thereafter, as stated by the European Society for Medical Oncology 3
Elderly patients with limited life expectancy (<5 years) may not require further follow-up unless symptoms develop, as recommended by the American Society of Hematology 3
Smoldering Multiple Myeloma patients should be followed up at 3-month intervals for the first year to establish the pattern of evolution, according to the National Comprehensive Cancer Network 6

Relying solely on SPE without IFE can lead to misdiagnosis, as warned by the International Myeloma Society 1
Overlooking light chain only or heavy chain only diseases can lead to misdiagnosis, as some monoclonal gammopathies may present with only light chains or heavy chains, according to the European Society for Medical Oncology 1
If a monoclonal protein is detected, additional laboratory tests, including complete blood count (CBC) with differential, comprehensive metabolic panel, and bone marrow aspiration and biopsy with flow cytometry and cytogenetics, should be performed to further evaluate the patient 4, 5, 6
Patients with suspected kidney involvement should be tested for non-albumin proteinuria, including assays for specific urine proteins like monoclonal light chains (Bence Jones proteins) 7
A narrow peak in the gamma region on SPEP requires further investigation for multiple myeloma, smoldering myeloma, MGUS, Waldenstrom's macroglobulinemia, solitary plasmacytoma, or amyloidosis 4, 6